| Treatment outcomes of primary central nervous system lymphoma : Multi-center retrospective study |
|
Joon Ho Moon, Dong Hwan Kim, Byung Min Ahn, Shi Nae Kim, Seok Bong Jeon, Jin Ho Baek, Jong Gwang Kim, Sang Kyun Sohn, Kyu Bo Lee, Jeong Hyun Hwang, Sung Kyoo Hwang, Je Jung Lee, Yeo Kyeoung Kim, Ik Joo Chung, Hyeoung Joon Kim, Deok Hwan Yang, Shin Jung, Young Rok Do, Ki Young Kwon, Hong Suk Song, Won Sup Lee |
|
고려대학교 의과대학 내과학교실 |
| 원저:원발성 중추신경계 림프종의 치료 성적에 대한 다기관 후향적 분석 |
|
문준호, Dong Hwan Kim, Byung Min Ahn, Shi Nae Kim, Seok Bong Jeon, Jin Ho Baek, Jong Gwang Kim, Sang Kyun Sohn, Kyu Bo Lee, Jeong Hyun Hwang, Sung Kyoo Hwang, Je Jung Lee, Yeo Kyeoung Kim, Ik Joo Chung, Hyeoung Joon Kim, Deok Hwan Yang, Shin Jung, Young Rok Do, Ki Young Kwon, Hong Suk Song, Won Sup Lee |
|
|
|
|
|
|
| Abstract |
Background : A primary central nervous system lymphoma (PCNSL) is a rare neoplasm with a
poor prognosis. The treatment of PCNSL involves a combination of chemotherapy, intrathecal
chemotherapy and radiotherapy. This study retrospectively evaluated the treatment outcomes and
prognostic factors of Korean patients with PCNSL.
Methods
: Between 1995 and 2003, 58 patients diagnosed with PCNSL from the multi-center
hospitals were enrolled in this study. Among 56 patients who had received treatment, 16 patients
were treated with radiotherapy alone, while 40 patients were treated with combined chemotherapy
(CHOP; 9 cases, high-dose methotrexate; 31 cases) and radiotherapy.
Results
: The median age of the patients was 58 years (range, 19-76). A diffuse large B-cell
lymphoma was diagnosed in 56 cases (96.6%), while a peripheral T-cell lymphoma was diagnosed
in 2 cases. Of the 47 patients who could be assessed for their response after treatment, a CR and PR was observed in 32 (68%) and 11 patients (23%), respectively, giving an overall response rate
of 91% (95% CI, 82～100%). The estimated 3-year overall survival rate for all the patients was 67±
7.9% and the 3-year disease free survival rate was 53±8.3%. The overall survival of the high-dose
methotrexate group was superior to that of the CHOP group (77±10% versus 47±19%, p=0.05).
Leukoencephalopathy was observed as a late complication in 9 patients (21%). No significant
prognostic factors affecting survival were found by univariate analysis.
Conclusions
: Approximately half of the patients could have long-term survival after treatment
in this study. High-dose methotrexate containing chemotherapy followed by radiotherapy was found
to be an effective treatment.(Korean J Med 71:654-661, 2006)
Key Words : Lymphoma, Central Nervous System, CHOP, High-dose methotrexate, Radiotherapy |
|
PDF Links
Full text via DOI
Download Citation
